Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: BI 201335 NA 120 mg capsule
Drug: BI 201335 NA 40 mg capsule

First Posted Date: 2012-10-12

Last Posted Date: 2015-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01704846

Locations: 🇯🇵
1220.53.08101 Boehringer Ingelheim Investigational Site, Sumida-ku,Tokyo, Japan

A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium (high dose) + Olodaterol
Drug: Tiotropium (low dose) + Olodaterol

First Posted Date: 2012-10-11

Last Posted Date: 2015-07-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01703845

Locations: 🇯🇵
1237.24.24001 Boehringer Ingelheim Investigational Site, Toshima-ku, Tokyo, Japan

Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: pantoprazole 40 mg STADA
Drug: BI 113608
Drug: BI 113608 PIB

First Posted Date: 2012-10-11

Last Posted Date: 2017-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT01703858

Locations: 🇩🇪
1314.3.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Linagliptin
Drug: Glimepiride

First Posted Date: 2012-10-10

Last Posted Date: 2015-01-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT01703286

Locations: 🇩🇪
1218.105.001 Boehringer Ingelheim Investigational Site, Neuss, Germany

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Placebo matching Olodaterol
Drug: Olodaterol

First Posted Date: 2012-09-28

Last Posted Date: 2014-11-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1137

Registration Number: NCT01696058

Locations: 🇺🇸
1222.52.02068 Boehringer Ingelheim Investigational Site, Chesterfield, Missouri, United States
🇺🇸
1222.52.02035 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
🇺🇸
1222.52.02091 Boehringer Ingelheim Investigational Site, Syracuse, New York, United States

and more 91 locations

Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Tiotropium 5 mcg qd
Drug: Tiotropium 2.5 mcg bid

First Posted Date: 2012-09-28

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 98

Registration Number: NCT01696071

Locations: 🇩🇪
205.441.49003 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇩🇪
205.441.49015 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪
205.441.49014 Boehringer Ingelheim Investigational Site, Frankfurt, Germany

and more 19 locations

Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: faldaprevir
Drug: omeprazole

First Posted Date: 2012-09-27

Last Posted Date: 2015-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT01694706

Locations: 🇩🇪
1220.59.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Olodaterol
Drug: Placebo matching Olodaterol
Drug: Tiotropium

First Posted Date: 2012-09-27

Last Posted Date: 2014-09-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1134

Registration Number: NCT01694771

Locations: 🇺🇸
1222.51.01079 Boehringer Ingelheim Investigational Site, Tamarac, Florida, United States
🇺🇸
1222.51.01076 Boehringer Ingelheim Investigational Site, Austell, Georgia, United States
🇺🇸
1222.51.01041 Boehringer Ingelheim Investigational Site, San Diego, California, United States

and more 87 locations

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BI 836858

First Posted Date: 2012-09-24

Last Posted Date: 2018-05-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01690624

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran
Drug: Placebo
Drug: BI 655075

First Posted Date: 2012-09-20

Last Posted Date: 2016-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 157

Registration Number: NCT01688830

Locations: 🇧🇪
1321.1.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy